Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition

Biochemical and Biophysical Research Communications

Volumn 471, Issue 1, 2016, Pages 184-190

  Shi, Sen ^a,b   Kanasaki, Keizo ^a   Koya, Daisuke ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b The First Affiliated Hospital of Sichuan Medical University   (China)

Author keywords

Dipeptidyl peptidase 4; Endothelial cell biology; Endothelial mesenchymal transition

Indexed keywords

BETA1 INTEGRIN; DIPEPTIDYL PEPTIDASE IV; GREEN FLUORESCENT PROTEIN; HOMODIMER; LINAGLIPTIN; MESSENGER RNA; MYC PROTEIN; RECOMBINANT ENZYME; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CELL FREE SYSTEM; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DRUG EFFECT; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; MESENCHYME CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL CULTURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; METABOLISM; PHYSIOLOGY;

CELLS, CULTURED; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LINAGLIPTIN; SITAGLIPTIN PHOSPHATE; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84958890242     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.01.154     Document Type: Article

References (34)

1. A.L. Sun, J.T. Deng, G.J. Guan, S.H. Chen, Y.T. Liu, J. Cheng, Z.W. Li, X.H. Zhuang, F.D. Sun, and H.P. Deng Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease Diabetes Vasc. Dis. Res. 9 2012 301 308
2. E.E. Mulvihill, and D.J. Drucker Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors Endocr. Rev. 35 2014 992 1019
3. T.A. Salles, L. dos Santos, V.G. Barauna, and A.C. Girardi Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure Int. J. Mol. Sci. 16 2015 4226 4249
4. C.F. Deacon What do we know about the secretion and degradation of incretin hormones? Regul. Pept. 128 2005 117 124
5. R. Mentlein Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul. Pept. 85 1999 9 24
6. D.J. Drucker Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Expert Opin. Investig. Drugs 12 2003 87 100
7. D.J. Drucker The biology of incretin hormones Cell Metab. 3 2006 153 165
8. B. Fleischer CD26: a surface protease involved in T-cell activation Immunol. Today 15 1994 180 184
9. T.D. Filippatos, V.G. Athyros, and M.S. Elisaf The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected] Expert Opin. Drug Metab. Toxicol. 10 2014 787 812
10. L.K. Golightly, C.C. Drayna, and M.T. McDermott Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors Clin. Pharmacokinet. 51 2012 501 514
11. M. Kirby, D.M. Yu, S. O'Connor, and M.D. Gorrell Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition Clin. Sci. 118 2010 31 41
12. S. Takai, H. Sakonjo, and D. Jin Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats J. Pharmacol. Sci. 125 2014 386 393
13. K. Kanasaki, S. Shi, M. Kanasaki, J. He, T. Nagai, Y. Nakamura, Y. Ishigaki, M. Kitada, S.P. Srivastava, and D. Koya Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen Diabetes 63 2014 2120 2131
14. S. Shi, S.P. Srivastava, M. Kanasaki, J. He, M. Kitada, T. Nagai, K. Nitta, S. Takagi, K. Kanasaki, and D. Koya Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition Kidney Int. 88 2015 479 489
15. A. Sundqvist, A. Zieba, E. Vasilaki, C. Herrera Hidalgo, O. Soderberg, D. Koinuma, K. Miyazono, C.H. Heldin, U. Landegren, P. Ten Dijke, and H. van Dam Specific interactions between Smad proteins and AP-1 components determine TGFbeta-induced breast cancer cell invasion Oncogene 32 2013 3606 3615
16. M. Zeisberg, and E.M. Zeisberg Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin Kidney Int. 88 2015 429 431
17. A.K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh VEGF receptor signalling - in control of vascular function Nat. Rev. Mol. Cell Biol. 7 2006 359 371
18. D. Medici, E.M. Shore, V.Y. Lounev, F.S. Kaplan, R. Kalluri, and B.R. Olsen Conversion of vascular endothelial cells into multipotent stem-like cells Nat. Med. 16 2010 1400 1406
19. C.A. Abbott, G.W. McCaughan, and M.D. Gorrell Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity FEBS Lett. 458 1999 278 284
20. A.M. Lambeir, C. Durinx, S. Scharpe, and I. De Meester Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit. Rev. Clin. Lab. Sci. 40 2003 209 294
21. J. Kameoka, T. Tanaka, Y. Nojima, S.F. Schlossman, and C. Morimoto Direct association of adenosine deaminase with a T cell activation antigen, CD26 Science 261 1993 466 469
22. C. Lopez-Otin, and L.M. Matrisian Emerging roles of proteases in tumour suppression Nat. Rev. Cancer 7 2007 800 808
23. G. Lu, Y. Hu, Q. Wang, J. Qi, F. Gao, Y. Li, Y. Zhang, W. Zhang, Y. Yuan, J. Bao, B. Zhang, Y. Shi, J. Yan, and G.F. Gao Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 Nature 500 2013 227 231
24. T. Kahne, U. Lendeckel, S. Wrenger, K. Neubert, S. Ansorge, and D. Reinhold Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review) Int. J. Mol. Med. 4 1999 3 15
25. K.A. Vora, G. Porter, R. Peng, Y. Cui, K. Pryor, G. Eiermann, and D.M. Zaller Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses BMC Immunol. 10 2009 19
26. S.H. Havale, and M. Pal Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes Bioorg Med. Chem. 17 2009 1783 1802
27. Y. Liu, Y. Hu, and T. Liu Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects Curr. Med. Chem. 19 2012 3982 3999
28. Y. Terawaki, T. Nomiyama, H. Takahashi, Y. Tsutsumi, K. Murase, R. Nagaishi, M. Tanabe, T. Kudo, K. Kobayashi, T. Yasuno, H. Nakashima, and T. Yanase Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis Diabetol. Metab. Syndr. 7 2015 44
29. M. Eckhardt, E. Langkopf, M. Mark, M. Tadayyon, L. Thomas, H. Nar, W. Pfrengle, B. Guth, R. Lotz, P. Sieger, H. Fuchs, and F. Himmelsbach 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes J. Med. Chem. 50 2007 6450 6453
30. S. Fitzpatrick, S. Taylor, S.W. Booth, and M.J. Newton The development of a stable, coated pellet formulation of a water-sensitive drug, a case study: development of a stable core formulation Pharm. Dev. Technol. 11 2006 521 528
31. M. Nabeno, F. Akahoshi, H. Kishida, I. Miyaguchi, Y. Tanaka, S. Ishii, and T. Kadowaki A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site Biochem. Biophys. Res. Commun. 434 2013 191 196
32. H.K. Tang, K.C. Chen, G.G. Liou, S.C. Cheng, C.H. Chien, H.Y. Tang, L.H. Huang, H.P. Chang, C.Y. Chou, and X. Chen Role of a propeller loop in the quaternary structure and enzymatic activity of prolyl dipeptidases DPP-IV and DPP9 FEBS Lett. 585 2011 3409 3414
33. C.A. Abbott, G.W. McCaughan, M.T. Levy, W.B. Church, and M.D. Gorrell Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain Eur. J. Biochem. 266 1999 798 810
34. J.R. Bjelke, J. Christensen, S. Branner, N. Wagtmann, C. Olsen, A.B. Kanstrup, and H.B. Rasmussen Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV J. Biol. Chem. 279 2004 34691 34697